The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)

Three large, dividend-paying companies are highlighted as attractively yielding and modestly undervalued: Pfizer (dividend yield ~6.81%, forward P/E ~8.5 vs five‑year avg 9.8) faces lower COVID-19 vaccine/Paxlovid demand and patent expirations but has pipeline upside including a potential GLP‑1 program; Verizon (yield ~6.93%, forward P/E ~8.2 vs five‑year avg 8.8) is a cash-generative telecom with ~146 million wireless accounts, extensive fiber and network coverage; and UPS (yield ~6.1%, forward P/E ~14.7 vs five‑year avg 15.4) is contending with reduced Amazon volumes, slowing growth and margin pressure while pursuing cost cuts and automation. The profile is income-oriented: elevated yields and below-average forward P/Es may appeal to income-focused investors despite company-specific operational risks.

Analysis

Market structure: High-yield blue-chips (PFE, VZ, UPS) act as bond-proxies and will attract income-focused ETFs and retirees if 10y yields remain >3.5% and equity yields >5.5%, pressuring lower-yield cyclicals. Direct winners are dividend-seeking funds and total-return buyers; losers include growth/tech that depend on rich multiple expansion. Logistics winners are asset-rich operators that convert scale to FCF; Amazon’s reduced shipments are a structural headwind for parcel incumbents.

Risk assessment: Tail risks include (1) Pfizer GLP-1 trial/regulatory failure or accelerated competitor wins that could erase >20–30% upside, (2) US drug-pricing reform cutting margins, (3) Verizon 5G/5G-capex overruns or subscriber churn raising leverage >4.5x EBITDA, and (4) UPS margin collapse if volume declines >10% YoY. Immediate (days) risk: dividend announcement/earnings shocks; short-term (weeks–months): FX and bond-yield moves; long-term (quarters–years): secular demand shifts and patent cliffs.

Trade implications: Favor yield capture with downside protection rather than naked long. Use buy-write/covered-call or cash-secured put structures at 3–9 month tenors to harvest income while limiting downside; deploy protective puts or collars around material binary events (FDA decisions, quarterly earnings). Rotate 2–5% allocations from high-valuation growth into these names, size by risk budget and liquidity.

Contrarian angles: Consensus worships headline yields but underestimates sustainability risks (pension & pension-related liabilities at UPS, incremental capex at VZ). Market may be underpricing Pfizer’s pipeline optionality — a positive GLP-1 outcome could re-rate P/E by 30%+ within 6–12 months. Conversely, if 10y >4.25% and credit spreads widen 50bps, yield-chasing flows will reverse quickly, repricing these names lower.

Key Decisions for Investors

• Initiate a 2–3% long position in PFE via buy-and-write: buy shares and sell 3-month calls ~5% OTM to boost ~6.5% yield; hedge downside with a 6–9 month 10% OTM put if FDA GLP-1 reads are due within 180 days. Close or unwind covered calls if positive GLP-1 approval or if dividend cut announced.
• Establish a 3% long position in VZ funded by selling a 6-month cash-secured put spread (sell 2% OTM, buy 5% further OTM) to collect premium; trim to 1% if net debt/EBITDA rises above 4.5x or if wireless postpaid churn rises >0.3ppt QoQ. Target total return (dividend + premium) >8% over 12 months.
• For UPS, avoid naked equity exposure >2%. Use a protective-collar: buy UPS shares (1–2% position), buy a 9–12 month put 10% OTM and sell a 9–12 month call 10% OTM to fund the hedge. Add to position only if operating margin improves sequentially by >100bp or daily parcels volume growth reverses to >+3% YoY.
• Rotate 2–4% of tech/growth exposure into these dividend plays now (sell high-multiple names showing >+30% 12-month forward P/E). Reallocate back if 10y Treasury yield rises above 4.25% and credit spreads widen +50bps, or if any of the three companies cut dividends.